I-Mab (IMAB) said Thursday it has agreed to buy Bridge Health Biotech for an upfront payment of $1.8 million, plus $1.2 million in non-contingent payments through 2027.
Bridge Health Biotech shareholders may also be entitled to future milestone payments of up to about $3.9 million, I-Mab said.
The deal, which will likely be completed in Q3, gives I-Mab upstream rights to the CLDN18.2 parental antibody for use in bispecific and multi-specific applications, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.